As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

The investment builds on Sanofi's alliance with mRNA specialist Translate Bio, which has already advanced vaccines for COVID-19 and seasonal influenza into clinical trials. mRNA vaccines work by ...

Sanofi and Translate's original agreement covered up to five mRNA-based vaccines for infectious diseases, and notably led to the development of a COVID-19 shot that is in phase 1/2 testing with ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

The growth trajectory of the global generic drugs market is underpinned by several key drivers. Firstly, the escalating incidence of chronic and non-chronic diseases worldwide underscores the vital ...

Infectious disease outbreaks have a bad habit of piling on at the worst possible times. The 1918 flu pandemic, also known as the Spanish flu, caught the world by surprise just as the First World War ...

Viruses like SARS-CoV-2 use sugar molecules to hide from the immune system, but scientists at Scripps Research have designed ...

Sugar coatings aren't only for candies; they also help viruses, like the ones that cause COVID-19, hide from their hosts' ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Rep. Marjorie Taylor Greene, R-Ga., declared that U.S. Food and Drug Administration approval for COVID-19 vaccines should be yanked, asserting that the jabs "are causing permanent harm and deaths." ...

Researchers at the University of Cologne and University Hospital Cologne have determined that the novel mRNA-based COVID-19 ...